ST. LOUIS–(BUSINESS WIRE)–#RNAbiomarkers–Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today announced it has appointed Mark Van Cleve, PhD as Vice President of Product Development.
“Mark brings a wealth of experience in IVD product development and a proven track record of success,” said Andrew Barnell, CEO of Geneoscopy. “He is the ideal person to lead our product development team.”
Dr. Van Cleve has more than 25 years of experience in the design and development of in vitro diagnostic products and technologies. Most recently, Dr. Van Cleve served as Head of R&D, Clinical Lab Menu at Ortho Clinical Diagnostics, where he oversaw the R&D department responsible for developing new assays, lifecycle management of existing products, and field triage. Previously, Dr. Van Cleve served as Vice President of R&D at Hycor Biomedical. Prior to his tenure at Hycor Biomedical, Dr. Van Cleve held roles at Agilent Technologies, Chiron Corporation, and BD Biosciences. Dr. Van Cleve holds a PhD in Biochemistry from the University of Illinois at Urbana-Champaign and a B.A. in Chemistry from Knox College.
“Geneoscopy is well positioned to leverage its stool-derived eukaryotic RNA extraction platform in a proven market with a demonstrated need for prevention and early detection,” said Dr. Van Cleve. “I am very excited for the opportunity to significantly improve human health as a member of the Geneoscopy team.”
Andrew Barnell, CEO